H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joseph Pantginis has given his Hold rating due to a combination of factors including Shattuck Labs’ financial position and the progress of its lead program, SL-325. The company recently reported its first-quarter 2025 results, showing an EPS that was better than expected, and it maintains a solid cash position expected to support operations into 2027. This financial stability provides a foundation for advancing SL-325, a promising DR3 antagonist antibody aimed at treating inflammatory bowel disease.
Despite the positive preclinical data and the potential differentiation of SL-325 from other treatments targeting the TL1A/DR3 signaling pathway, the program is still in early stages with an IND filing expected in the third quarter of 2025 and a Phase 1 trial projected to start soon after. Given these timelines, the Hold rating reflects a cautious optimism, acknowledging the potential of SL-325 while considering the inherent risks and uncertainties associated with early-stage drug development.
According to TipRanks, Pantginis is an analyst with an average return of -19.8% and a 22.78% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Actinium Pharmaceuticals.